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Background and purpose: Recently, orthostatic hypotension was observed in patients with benign prostatic hyperplasia who
are taking vardenafil (a PDE 5 inhibitor) and terazosin (a long acting alpha blocker). Therefore, this study was performed with
DA-8159 (a long acting PDE 5 inhibitor) and terazosin in rats to find whether or not pharmacokinetic and pharmacodynamic
interactions between the two drugs were observed.
Experimental approach: Pharmacokinetic and pharmacodynamic (changes in blood pressure) interactions between DA-8159
and terazosin were evaluated after simultaneous i.v. and p.o. administration of DA-8159 (30 mg kg1) and terazosin
(5 mg kg1) to male Sprague–Dawley rats.
Key results: After simultaneous i.v. and p.o. administration of terazosin and DA-8159, the total area under the plasma
concentration–time curve from time zero to time infinity (AUC) of terazosin became significantly greater (57.4 and 75.4%
increase for i.v. and p.o. administration, respectively) than those of without DA-8159. The blood pressure dropping effect was
considerable after simultaneous p.o. administration of DA-8159 and terazosin compared with each drug alone.
Conclusions and implications: The significantly greater AUC of terazosin after both simultaneous i.v. and p.o. administration
of both drugs could be due to the hepatic (both i.v. and p.o.) and intestinal (p.o.) inhibition of the metabolism of terazosin via
CYP3A1 and/or 3A2 by DA-8159, since both DA-8159 and terazosin are metabolized via CYP3A1 and/or 3A2 in rats. The blood
pressure lowering effect after simultaneous p.o. administration of both drugs could be due to significant increase in plasma
concentrations of terazosin.
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Abbreviations: Ae0–24 h, percentage of dose excreted in 24 h urine; AUC, total area under the plasma concentration–time curve
from time zero to time infinity; Cmax, peak plasma concentration; CL, time-averaged total body clearance;
CLint, intrinsic clearance; CLR, time-averaged renal clearance; CLNR, time-averaged nonrenal clearance; F,
extent of absolute oral bioavailability; GI24 h, percentage of dose recovered from the entire gastrointestinal tract
(including its contents and faeces) at 24 h; Km, Michaelis–Menten constant; MRT, mean residence time; Tmax,
time to reach a Cmax; Vmax, maximum velocity; Vss, apparent volume of distribution at steady state
Introduction
A new inhibitor of cyclic guanosine monophosphate
(cGMP)-specific phophodiesterase type 5 (PDE 5), DA-8159
(Udenafil), 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethyl
amidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-
pyrazolo-(4,3-d)pyrimidine-7-one was developed (Research
Laboratory of Dong-A Pharmaceutical Company, Yongin,
South Korea) for the treatment of male erectile dysfunction.
Phase I studies on DA-8159 conducted in both the UK and
Korea have shown that the drug has unique pharmacokinetic
profiles (Tmax of 1.0–1.5 h and a half-life of 11–13 h after oral
administration of the drug) suggesting that the drug could
have a relatively rapid onset of action and sufficiently long
duration of action to make it effective for up to 24 h
Received 23 November 2006; revised 10 January 2007; accepted 16 January
2007; published online 12 March 2007
Correspondence: Professor MG Lee, College of Pharmacy and Research
Institute of Pharmaceutical Sciences, Seoul National University, San 56-1,
Shinlim-Dong, Kwanak-Gu, Seoul 151-742, South Korea.
E-mail: leemg@snu.ac.kr
British Journal of Pharmacology (2007) 151, 24–34
& 2007 Nature Publishing Group All rights reserved 0007–1188/07 $30.00
www.brjpharmacol.org
compared with other PDE 5 inhibitors (Bahng et al., 2002;
Padma-Nathan et al., 2004). Phase II clinical data of DA-8159
presented at the 11th World Congress of the International
Society for the Sexual and Impotence Research showed that
in men with mild-to-severe erectile dysfunction, the drug
produced a significant improvement in erectile function
after 12 weeks of treatment (Salem et al., 2006). Prior studies
have also demonstrated a selectivity profile of DA-8159
that is similar to sildenafil but unlike tadalafil, the drug
does not inhibit the PDE 11 isozyme and thus would not be
expected to produce significant myalgia (Salem et al., 2006).
The hepatic microsomal cytochrome P450 (CYP) 3A4 was
identified as the major enzyme responsible for the formation
of DA-8164 (N-dealkylated DA-8159) based on human
liver microsomes (Ji et al., 2004). Recently, it was reported
that the metabolism of DA-8159 and the formation of
DA-8164 were mediated via CYP3A1 and/or 3A2 (not
via CYP1A1/2, 2B1/2, 2D1 and 2E1) in male Sprague–Dawley
rats (Kim et al., 2005b). Based on the in vivo studies, DA-8159
was metabolized to DA-8164 in mice, rats, rabbits, dogs
and humans (Shim et al., 2005). The pharmacological
actions, pharmacokinetics and metabolism, and clinical
studies on DA-8159 have been reviewed (Kim et al.,
2005a). DA-8159, a fourth PDE 5 inhibitor, is marketed in
Korea under the brand name of Zydena in 100 and
200 mg tablet strengths for the treatment of male erectile
dysfunction.
a-Adrenoceptor blockers are commonly used to treat
benign prostatic hyperplasia (BPH) and/or hypertension.
Evidence is growing that BPH and erectile dysfunction are
closely associated, independent of patient age (Giuliano
et al., 2006). PDE 5 inhibitors, the most effective oral
therapies for erectile dysfunction, are mild vasodilators
associated with small decreases in blood pressure because
the PDE 5 enzyme is found within the vascular smooth
muscle cells in the walls of systemic arteries and veins
(Haning et al., 2003; Kloner, 2005). The concurrent use of an
a-adrenergic blocker with a PDE 5 inhibitor may result in an
excessive reduction in blood pressure. Recently, it was
reported that tadalafil (a long-acting PDE 5 inhibitor)
increases the hypotensive effect of doxazosin (a long-acting
and nonselective a-blocker) prescribed for both hypertension
and BPH (Kloner et al., 2004; Kloner, 2005). Also it was
shown that sildenafil given with doxazosin, and vardenafil
given with terazosin (a long-acting and nonselective
a-blocker) evoked orthostatic hypotension in some patients
(Kloner et al., 2004). Terazosin is one of long-acting
a-blockers and commonly used agent for treating BPH and/or
hypertension. Therefore, this study was performed with DA-
8159 and terazosin in rats to find the reasons for pharma-
cokinetic and pharmacodynamic (changes in blood pressure)
interactions between the two drugs.
This paper reports the reasons for the pharmacokinetic and
pharmacodynamic (changes in blood pressure) interactions
between DA-8159 and terazosin after simultaneous intrave-
nous (i.v.) and per os (p.o.) administration of the two drugs
to male SpragueDawley rats. The CYP isozymes responsible
for the metabolism of terazosin in rats does not seem to be
published to date. Hence, the metabolism of terazosin via
CYP3A1 and/or 3A2 in rats is reported.
Methods
Animals
Male SpragueDawley rats of 7–9 weeks of age (weighing
220–330 g) purchased from Taconic Farms Inc. (Samtako Bio
Korea, O-San, South Korea) were housed in a light-controlled
room (light: 0700–1900 h, dark: 1900–0700 h) kept at a
temperature of 20711C and a relative humidity of 5075%
(Animal Center for Pharmaceutical Research, College of
Pharmacy, Seoul National University, Seoul, South Korea).
The rats were housed in metabolic cages (Tecniplast, Varese,
Italy) with a supply of filtered pathogen-free air, and food
(Samyang Company, Pyeongtaek, South Korea) and water ad
libitum. The protocol of this study was approved by Animal
Care and Use Committee of College of Pharmacy of Seoul
National University.
I.v.study
In the early morning, the jugular vein (for drug administra-
tion) and the carotid artery (for blood sampling) of each rat
were cannulated with a polyethylene tube (Clay Adams,
Parsippany, NJ, USA) whereas each rat was under light ether
anesthesia (Kim et al., 1993). Both cannulas were exteriorized
to the dorsal side of the neck where each cannula was
terminated with a long silastic tube (Dow Corning Midland,
MI, USA). Both silastic tubes were inserted into a wire sheath
to allow free movement of the rat. Each rat was housed
individually in a rat metabolic cage (Daejong Scientific
Company, Seoul, South Korea) and allowed for 4–5 h to
recover from anesthesia before the study began. They were
not restrained during the study.
DA-8159 (dissolved in 0.05 M citric acid to yield
15 mg ml1) at a dose of 30 mg kg1 (n¼8), terazosin
(dissolved in 0.05 M citric acid to yield 2.5 mg ml1) at a
dose of 5 mg kg1 (n¼8) and both (n¼10) were infused for
1 min via the jugular vein of rats. An approximately 0.12 ml
(for DA-8159 alone or terazosin alone) or 0.22 ml (for both
DA-8159 and terazosin) aliquot of blood sample was
collected via the carotid artery at 0 (to serve as a control),
1 (at the end of the infusion), 5, 15, 30, 60, 120, 180, 240,
360, 480, 600 or 720 min after the start of the infusion of the
drug(s). Blood samples were centrifuged immediately and a
50 ml aliquot (for DA-8159 alone or terazosin alone) or two
50 ml aliquots (for both DA-8159 and terazosin) of plasma
sample were collected in a 1.5 ml polyethylene tube, and was
stored in a 701C freezer (Revco ULT 1490 D-N-S; Western
Mednics, Ashville, NC, USA) until high performance liquid
chromatographic (HPLC) analysis of DA-8159, DA-8164
and terazosin. At the end of the experiment (24 h), each
metabolic cage was rinsed with 10 ml of distilled water, and
the rinsings were combined with 24-h urine sample. After
measuring the exact volume of the combined urine samples,
two 50 ml aliquots of the combined urine sample were stored
in a 701C freezer until HPLC analysis of DA-8159, DA-8164
and terazosin. At the same time (24 h), each rat was sacrificed
through cervical dislocation and exsanguinated. And then
its abdomen was opened and the entire gastrointestinal tract
(including its contents and feces) of each rat was removed,
transferred into a beaker that contained 50 ml of methanol
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(to facilitate the extraction of DA-8159, DA-8164 and terazosin)
and cut into small pieces with scissors. After it was stirred with
a glass rod for 1 min, two 50ml aliquots of the supernatant were
collected from each beaker and stored in a 701C freezer until
HPLC analysis of DA-8159, DA-8164 and terazosin.
Oral study
DA-8159 (the same solution that was used in the i.v. study) at
a dose of 30 mg kg1 (n¼8), terazosin (the same solution that
was used in the i.v. study) at a dose of 5 mg kg1 (n¼ 7), and
both (n¼8) were orally administered to rats using a feeding
tube. The same dose of terazosin (for 7 days) (n¼8), the same
dose of single DA-8159 (just after seventh dose of the same
volume of 0.05 M citric acid) (n¼10), and both (DA-8159 was
administered just after seventh dose of terazosin) (n¼9) were
also administered orally to rats. An approximately 0.12 (for DA-
8159 alone and terazosin alone) or 0.22 ml (for both DA-8159
and terazosin) aliquot of blood sample was collected via the
carotid artery at 0, 15, 30, 60, 90, 120, 180, 240, 360, 480, 600,
720 or 1440min after oral administration of the drug(s). Blood
samples were collected on day 7 just after administration of the
drugs. Other procedures were similar to those in the i.v. study.
Measurement of Vmax, Km and CLint for the disappearance of
terazosin with and without DA-8159 in hepatic microsomal
fractions
The procedures were similar to the reported methods (Shim
et al., 2004). The livers of control rats (n¼5) were homo-
genized in ice-cold buffer (0.154 M KCl/50 mM Tris-HCl in
1 mM ethylenediamine tetraacetic acid (EDTA), pH 7.4). The
homogenate was then centrifuged at 10 000 g for 30 min and
the supernatant fraction was further centrifuged at 1 00 000 g
for 90 min. Protein content was measured using the reported
method (Bradford, 1976). The Vmax (the maximum velocity)
and Km (the Michaelis–Menten constant; the concentration
at which the rate is one-half of Vmax) for the disappearance of
terazosin with and without DA-8159 were determined after
incubating the above microsomal fraction (equivalent to
1.0 mg protein), a 50 ml aliquot of distilled water that
contained 0.5, 1, 2, 5, 20, 50 and 100 mM of terazosin, with
or without a 10 ml aliquot of 0.5 M citrate buffer that
contained 100mg of DA-8159 and a 50 ml aliquot of 0.1 M
phosphate buffer that contained 1 mM of nicotinamide
adenine dinucleotide phosphate (NADPH) in a final volume
of 500 ml by the addition of 0.1 M phosphate buffer, pH 7.4, in
a thermomixer (Thermomixer 5436; Eppendorf, Hamburg,
Germany) kept at 371C and at a rate of 500 oscillations per
min (o.p.m). All of the above microsomal incubation
conditions were linear. The reaction was terminated by
the addition of a 300 ml aliquot of 1 N NaOH after 30 min
incubation. Terazosin concentrations were measured by
the reported HPLC method. The kinetic constants (Km and
Vmax) for the disappearance of terazosin with or without
DA-8159 were calculated using the nonlinear regression
method (Duggleby, 1995). The intrinsic clearance (CLint) for
the disappearance of terazosin with and without DA-8159
was calculated by dividing the respective Vmax by the
respective Km.
I.v. administration of terazosin to rats pretreated with
troleandomycin or dexamethasone phosphate
Rats received a single intraperitoneal (i.p.) injection of
500 mg (5 ml) kg1 of troleandomycin (a main inhibitor of
CYP3A1 and 3A2 in rats (Correia, 1995); dissolved in 0.9%
NaCl-injectable solution acidified to pH 4.0 with 1 N HCl
(Sinclair et al., 2000)), or three daily i.p. injection of 50 mg
(5 ml) kg1 of dexamethasone phosphate (a main inducer of
CYP3A1 and 3A2 in rats (Correia, 1995); dissolved in 0.9%
NaCl-injectable solution (Roos et al., 1993)). An experiment
was performed after 2 h for the troleandomycin-pretreated
rats (Sinclair et al., 2000) and on day 4 for dexamethasone
phosphate-pretreated rats (Roos et al., 1993). Terazosin (the
same solution that was used in the i.v. study) at a dose of
10 mg kg1 was infused for 1 min via the jugular vein of rats
pretreated with troleandomycin (n¼7) or dexamethasone
phosphate (n¼7) and their control rats (n¼8). Other
procedures were similar to those in the i.v. study already
described.
Pharmacodynamic (blood pressure) changes after oral
administration of DA-8159, terazosin, or both and control rats
The carotid artery was cannulated with polyethylene tubes
(Kim et al., 1993) to monitor the arterial systolic blood
pressure up to 10 h in the rats after p.o. administration of
DA-8159 at a dose of 30 mg kg1 (n¼3), terazosin at a dose of
5 mg kg1 (n¼3), or both (n¼3) and control (administration
of vehicle, 0.05 M citric acid) rats (n¼3) without blood
sampling. The arterial systolic blood pressure readings were
recorded using a pressure transducer and a bridge amplifier
connected online to the artery and to a PowerLab system
(PowerLab, Version 5; ADI Instruments, Pty Ltd, Castle Hill,
NSW, Australia).
HPLC analysis of DA-8159, DA-8164 and terazosin
Concentrations of DA-8159 and DA-8164 in the above
samples were analyzed by a slight modification of the
reported HPLC method (Shim et al., 2002); a biological
sample of 50 ml instead of 100 ml was used. To a 50 ml aliquot
of biological sample, a 0.1 ml aliquot of 0.1 N Na2CO3 that
contained 3mg/ml of sildenafil (an internal standard) and a
1 ml aliquot of ethylether were added. After vortex-centrifu-
gation at 16 000 g for 8 min, the ether layer was collected and
dried under a gentle stream of nitrogen gas at 301C. A 100ml
aliquot of the mobile phase was added to reconstitute the
residue and a 50 ml aliquot was directly injected onto a
reversed-phase (C18) HPLC column. The mobile phase,
20 mM KH2PO4:acetonitrile (72:28; v/v), was run at a flow
rate of 1.5 ml min1, and the column effluent was monitored
using an ultraviolet detector set at 292 nm at room
temperature. The retention times of DA-8159, DA-8164 and
the internal standard (sildenafil) were approximately 9.7,
17.1 and 6.9 min, respectively. The detection limits of DA-
8159 and DA-8164 in plasma and urine were all 0.05 mg ml1.
The coefficients of variation of the assay (within- and
between-days) were below 10.1% for the plasma and 9.91%
for the urine samples.
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Concentrations of terazosin in the above samples were
analyzed by a slight modification of the reported HPLC
method (Cheah et al., 2000); a biological sample of 50 ml
instead of 500ml, and column oven of 501C instead of room
temperature were used. To a 50-ml aliquot of biological
sample, a 25-ml aliquot of 1 N NaOH, a 50-ml aliquot of
distilled water that contained 0.6mg ml1 of the internal
standard (prazosin hydrochloride) and a 1-ml aliquot of
dichloromethane were added. After vortex-centrifugation at
16 000 g for 8 min, the organic layer was collected and dried
under a gentle stream of nitrogen gas at room temperature. A
150-ml aliquot of the mobile phase was added to reconstitute
the residue and a 50-ml aliquot was directly injected onto a
reversed-phase (C18) HPLC column. The mobile phase, 10 mM
Na2HPO4:acetonitrile:tetrahydrofuran (76:22:2; v/v/v) adjusted
to pH 6.5 using 85% phosphoric acid, was run at a flow rate of
1.3 ml min1, and the column effluent was monitored using
a fluorescence detector set at an excitation wavelength of
250 nm and an emission wavelength of 370 nm at 501C using
column oven (Eldex CH-150, Eldex Laboratories Inc, CA, USA).
The retention times of terazosin and the internal standard
(prazosin hydrochloride) were approximately 6.1 and 11.6 min,
respectively. The detection limits of terazosin in plasma and
urine were all 5 ngml1. The coefficients of variation of the
assay (within- and between-days) were below 7.41% for the
plasma and 9.38% for the urine samples.
Pharmacokinetic analysis
The total area under the plasma concentration–time curve
from time zero to time infinity (AUC) was calculated using
the trapezoidal rule–extrapolation method. This method
uses the logarithmic trapezoidal rule for the calculation of
the area during the declining plasma-level phase (Chiou,
1978), and the linear trapezoidal rule for the rising plasma-
level phase. The area from the last datum point to time
infinity was estimated by dividing the last measured plasma
concentration by the terminal-phase rate constant.
Standard methods (Gibaldi and Perrier, 1982) were used to
calculate the following pharmacokinetic parameters using
the noncompartmental analysis (WinNonlin; Pharsight
Corporation, Mountain View, CA, USA); the time-averaged
total body (CL), renal (CLR) and nonrenal (CLNR) clearances,
terminal half-life (t1/2), first moment of AUC (AUMC), mean
residence time (MRT), apparent volume of distribution at a
steady state (Vss) and extent of absolute oral bioavailability
(F) (Kim et al., 1993). The peak plasma concentration (Cmax)
and time to reach a Cmax (Tmax) were read directly from the
experimental data.
The harmonic mean method was used to calculate the
mean values of Vss (Chiou, 1979), terminal t1/2 (Eatman et al.,
1977) and each clearance (Chiou, 1980).
Statistical analysis
A P-value of o0.05 was considered to be statistically
significant using a t-test between the two means for the
unpaired data. All results are expressed as mean7s.d., except
median (ranges) for Tmax.
Chemicals
DA-8159, DA-8164 and sildenafil citrate (an internal
standard of HPLC analysis of DA-8159 and DA-8164) were
supplied from Research Laboratory of Dong-A Pharma-
ceutical Company. Tris(hydroxymethyl) aminomethane
(Tris)-buffer, terazosin, dexamethasone phosphate, troleandomy-
cin, reduced form of b-nicotinamide adenine dinucleotide
phosphate (NADPH; as a tetrasodium salt) and EDTA were
purchased from Sigma–Aldrich Corporation (St Louis, MO,
USA). Prazosin hydrochloride (an internal standard of HPLC
analysis of terazosin) was purchased from Tokyo Chemical
Industry Corporation (Tokyo, Japan). Other chemicals were
of reagent grade or HPLC grade.
Results
Pharmacokinetics of DA-8159 and DA-8164 after single i.v.
administration of DA-8159 with or without simultaneous single
i.v. administration of terazosin to rats
After i.v. administration of DA-8159 with or without i.v.
terazosin, the mean arterial plasma concentration–time
profiles of DA-8159 and DA-8164 are shown in Figure 1a
and b, respectively, and some relevant pharmacokinetic
parameters are listed in Table 1. The pharmacokinetic para-
meters of DA-8159 listed in Table 1 were not significantly
different between two groups of rats, except significantly slow
CLR (73.7% decrease) and significantly smaller percentages of
i.v. dose of DA-8159 excreted in 24 h urine (Ae0–24 h; 62.3%
decrease) and recovered from the gastrointestinal tract
(including its contents and feces) at 24 h (GI24 h; 55.5%
decrease) as unchanged DA-8159 in rats with terazosin.
After i.v. administration of DA-8159 with or without
terazosin, the formation of DA-8164 became rapid; DA-
8164 was detected in plasma from the first blood sampling
time (1 min) for both groups of rats (Figure 1b), and reached
Tmax values of DA-8164 rapidly; the values were 45 and
30 min for with and without terazosin, respectively (they
were not significantly different). The pharmacokinetic
parameters of DA-8164 listed in Table 1 were also not
significantly different between the two groups of rats, except
significantly slower CLR (65.3% decrease) and significantly
smaller Ae0–24 h (48.1% decrease; expressed in terms of the
i.v. dose of DA-8159) in rats with terazosin.
Pharmacokinetics of terazosin after single i.v. administration of
terazosin with or without simultaneous single i.v. administration
of DA-8159 to rats
After i.v. administration of terazosin with and without i.v.
DA-8159, the mean arterial plasma concentration–time
profiles of terazosin are shown in Figure 1c, and some
relevant pharmacokinetic parameters are also listed in
Table 1. After simultaneous i.v. administration with DA-
8159, the differences in the pharmacokinetic parameters
of terazosin are as follows: the AUC became significantly
greater (57.4% increase), MRT became significantly longer
(86.2% increase), and CL, CLR and CLNR became significantly
slower (37.2, 60.8 and 32.4% decrease, respectively) than
those after terazosin alone.
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Pharmacokinetics of DA-8159 and DA-8164 after oral
administration of DA-8159 with or without simultaneous oral
administration of terazosin to rats
After single p.o. administration of DA-8159 with and with-
out single p.o. terazosin, the mean arterial plasma concen-
tration–time profiles of DA-8159 and DA-8164 are shown in
Figure 2a and b, respectively, and some relevant pharmaco-
kinetic parameters are listed in Table 2. The pharmacokinetic
parameters of both DA-8159 and DA-8164 listed in Table 2
were not changed significantly by terazosin.
After p.o. administration of single DA-8159 with and
without daily p.o. administration of terazosin for 7 days, the
mean arterial plasma concentration–time profiles of DA-
8159 and DA-8164 are shown in Figure 3a and b, respec-
tively, and some relevant pharmacokinetic parameters are
listed in Table 3. The pharmacokinetic parameters of both
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Figure 1 Arterial plasma concentration–time profiles of DA-8159 (a) and DA-8164 (b) after single i.v. administration of DA-8159 at a dose of
30 mg kg1 with (n¼10) or without (n¼8) simultaneous single i.v. administration of terazosin at a dose of 5 mg kg1 to rats, and of terazosin
(c) after single i.v. administration of terazosin at a dose of 5 mg kg1 with (n¼10) or without (n¼8) simultaneous single i.v. administration of
DA-8159 at a dose of 30 mg kg1 to rats. Data are presented as mean7s.d.
Table 1 Pharmacokinetic parameters of DA-8159 and DA-8164 after single i.v. administration of DA-8159 at a dose of 30 mg kg1 without and with
simultaneous single i.v. administration of terazosin at a dose of 5 mg kg1, and of terazosin after single i.v. administration of terazosin at a dose of
5 mg kg1 without and with simultaneous single i.v. administration of DA-8159 at a dose of 30 mg kg1 to rats
Parameter DA-8159 Parameter Terazosin
Without terazosin With terazosin Without DA-8159 With DA-8159
DA-8159 Terazosin
AUC (mg min ml1) 514756.0 553777.3 AUC (mg min ml1) 202727.4 318770.3a
Terminal t1/2 (min) 192770.4 212769.2 Terminal t1/2 (min) 141728.2 143773.0
MRT (min) 85.3722.5 101732.0 MRT (min) 84.3711.2 157739.3a
Vss (ml kg
1) 463071520 516071430 Vss (ml kg
1) 20207488 24207404
CL (ml min1 kg1) 58.476.26 54.378.61 CL (ml min1 kg1) 24.773.41 15.573.87a
CLR (ml min
1 kg1) 3.2171.27 0.84471.11b CLR (ml min
1 kg1) 6.6971.65 2.6272.40c
CLNR (ml min
1 kg1) 54.774.86 53.078.23 CLNR (ml min
1 kg1) 17.972.26 12.172.99a
Ae0–24 h (% of DA-8159 dose) 6.2971.68 2.3771.75
b Ae0–24 h (% of terazosin dose) 28.672.73 22.7711.5
GI24 h (% of DA-8159 dose) 1.4670.693 0.65070.418
d GI24 h (% of terazosin dose) 0.24570.238 0.30870.242
DA-8164
AUC (mg min ml1) 113732.5 115740.0
Terminal t1/2 (min) 134775.4 124768.0
CLR (ml min
1 kg1) 0.38670.0741 0.13470.117b
Cmax (mg ml
1) 0.41170.294 0.38270.260
Tmax (min) 30 (15–30) 45 (15–120)
Ae0–24 h (% of DA-8159 dose) 0.15070.0534 0.077870.0317
d
GI24 h (% of DA-8159 dose) 0.32570.255 0.31470.260
Abbreviations: Ae0–24 h, percentage of dose excreted in 24 h urine; AUC, total area under the plasma concentration–time curve from time zero to time infinity; CL,
time-averaged total body clearance; CLR, time-averaged renal clearance; CLNR, time-averaged nonrenal clearance; Cmax, peak plasma concentration; GI24 h,
percentage of dose recovered from the entire gastrointestinal tract (including its contents and feces) at 24 h; i.v., intravenous; MRT, mean residence time; Tmax,
time to reach a Cmax; t1/2, half-life; Vss, apparent volume of distribution at steady state.
Data are expressed as mean7s.d. (without terazosin, n¼8; with terazosin, n¼10 for DA-8159, without DA-8159, n¼ 8; with DA-8159, n ¼10 for terazosin).
Significant difference from without DA-8159, aPo0.001 and cPo0.01. Significantly different from without terazosin, bPo0.001 and dPo0.01.
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DA-8159 and DA-8164 listed in Table 3 were also not
changed significantly by terazosin.
Pharmacokinetics of terazosin after oral administration of
terazosin with or without simultaneous oral administration
of DA-8159 to rats
After single p.o. administration of terazosin with and
without single p.o. administration of DA-8159, the mean
arterial plasma concentration–time profiles of terazosin are
shown in Figure 2c, and some relevant pharmacokinetic
parameters are also listed in Table 2. After simultaneous
administration with DA-8159, the changes in the pharma-
cokinetic parameters of terazosin are as follows: the AUC
became significantly greater (75.4% increase), CLR became
significantly faster (28.7% increase), Cmax became signifi-
cantly higher (108% increase), and Ae0–24 h (138% increase)
and GI24 h (79.0% decrease) became significantly greater and
smaller, respectively, than those after terazosin alone.
After 7 days p.o. administration of terazosin with single
p.o. administration of DA-8159, the mean arterial plasma
concentration–time profiles of terazosin are shown in Figure
3c, and some relevant pharmacokinetic parameters are also
listed in Table 3. After single p.o. administration of DA-8159,
the changes in the pharmacokinetic parameters of terazosin
are as follows: the AUC became significantly greater (138%
increase), CLR became significantly slower (61.2% decrease),
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Figure 2 Arterial plasma concentration–time profiles of DA-8159 (a) and DA-8164 (b) after single p.o. administration of DA-8159 at a dose of
30 mg kg1 with (n¼8) or without (n¼8) simultaneous single p.o. administration of terazosin at a dose of 5 mg kg1 to rats, and of terazosin
(c) after single p.o. administration of terazosin at a dose of 5 mg kg1 with (n¼8) or without (n¼7) simultaneous single p.o. administration of
DA-8159 at a dose of 30 mg kg1 to rats. Data are presented as mean7s.d.
Table 2 Pharmacokinetic parameters of DA-8159 and DA-8164 after single p.o. administration of DA-8159 at a dose of 30 mg kg1 without and with
simultaneous single p.o. administration of terazosin at a dose of 5 mg kg1, and of terazosin after single p.o. administration of terazosin at a dose of
5 mg kg1 without and with simultaneous single p.o. administration of DA-8159 at a dose of 30 mg kg1 to rats
Parameter DA-8159 Parameter Terazosin
Without terazosin With terazosin Without DA-8159 With DA-8159
DA-8159 Terazosin
AUC (mg min ml1) 133762.4 137730.3 AUC (mg min ml1) 134733.5 235749.7a
Terminal t1/2 (min) 298750.8 3067139 Terminal t1/2 (min) 3037119 208753.6
CLR (ml min
1 kg1) 1.9171.21 1.8971.18 CLR (ml min
1 kg1) 4.6470.824 5.9771.77b
Cmax (mg ml
1) 0.30570.0883 0.27470.0775 Cmax (mg ml
1) 0.30370.242 0.63170.118c
Tmax (min) 30 (15–90) 30 (15–45) Tmax (min) 30 (15–360) 45 (30–60)
Ae0–24 h (% of DA-8159 dose) 0.87870.259 1.0970.480 Ae0–24 h (% of terazosin dose) 12.472.28 29.577.31
a
GI24 h (% of DA-8159 dose) 2.1073.20 1.5270.956 GI24 h (% of terazosin dose) 7.0473.38 1.4871.06
a
F (%) 25.9 24.8 F (%) 67.8 73.9
DA-8164
AUC (mg min ml1) 104735.4 114734.0
Terminal t1/2 (min) 153747.0 194771.0
CLR (ml min
1 kg1) 0.42870.224 0.22770.345
Cmax (mg ml
1) 0.27270.106 0.20170.0583
Tmax (min) 180 (60–360) 45 (30–480)
Ae0–24 h (% of DA-8159 dose) 0.17670.113 0.10870.0492
GI24 h (% of DA-8159 dose) 0.65470.286 0.62170.258
Abbreviations: AUC, total area under the plasma concentration–time curve from time zero to time infinity; CLR, time-averaged renal clearance; Cmax, peak plasma
concentration; t1/2, half-life; Tmax, time to reach a Cmax; Ae0–24 h, percentage of dose excreted in 24 h urine; F, extent of absolute oral bioavailability; GI24 h,
percentage of dose recovered from the entire gastrointestinal tract (including its contents and feces) at 24 h; p.o., per os.
Data are expressed as mean7s.d., (without terazosin, n¼8; with terazosin, n¼8 for DA-8159, without DA-8159, n¼7; with DA-8159, n¼8 for terazosin).
Significant difference from without DA-8159, aPo0.001, bPo0.05 and cPo0.01.
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Cmax became significantly higher (147% increase) and Tmax
became significantly shorter (62.5% decrease) than those
without DA-8159.
Measurement of Vmax, Km and CLint for the disappearance of
terazosin with and without DA-8159 in hepatic microsomal
fractions
The Vmax, Km and CLint for the disappearance of terazosin
with or without DA-8159 are listed in Table 4. The Vmax and
Km for the disappearance of terazosin became significantly
slower (13.8% decrease) and higher (123% increase), respec-
tively, in the presence of DA-8159, suggesting that the
maximum velocity for the disappearance (mainly due to
metabolism) of terazosin was slower and affinity of terazosin
to enzymes (mainly to CYP3A1 and/or 3A2) decreased by
DA-8159. Hence, the CLint for the disappearance of terazosin
became significantly slower (62.0% decrease) in the presence
of DA-8159, suggesting that the hepatic metabolism of
terazosin was inhibited by DA-8159.
Pharmacokinetics of i.v. terazosin in rats pretreated with
dexamethasone phosphate or troleandomycin
After i.v. administration of terazosin in rats pretreated with
dexamethasone phosphate or troleandomycin, the mean
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Figure 3 Arterial plasma concentration–time profiles of DA-8159 (a) and DA-8164 (b) after single p.o. administration of DA-8159 at a dose of
30 mg kg1 with (n¼9) or without (n¼10) simultaneous p.o. administration of terazosin at a dose of 5 mg/kg/day for 7 days to rats, and of
terazosin (c) after p.o. administration of terazosin at a dose of 5 mg/kg/day for 7 days with (n¼9) or without (n¼8) simultaneous single p.o.
administration of DA-8159 at a dose of 30 mg kg1 to rats. Data are presented as mean7s.d.
Table 3 Pharmacokinetic parameters of DA-8159 and DA-8164 after single p.o. administration of DA-8159 at a dose of 30 mg kg1 without and with
simultaneous p.o. administration of terazosin at a dose of 5 mg kg1 per day for 7 days, and of terazosin after p.o. administration of terazosin at a dose of
5 mg kg1 per day for 7 days without and with simultaneous single p.o. administration of DA-8159 at a dose of 30 mg kg1 to rats
Parameter DA-8159 Parameter Terazosin
Without terazosin With terazosin Without DA-8159 With DA-8159
DA-8159 Terazosin
AUC (mg min ml1) 137712.5 134720.7 AUC (mg min ml1) 124716.7 295738.7a
Terminal t1/2 (min) 310778.1 289798.0 Terminal t1/2 (min) 305745.2 254763.5
CLR (ml min
1 kg1) 2.2572.73 1.5772.05 CLR (ml min kg
1) 8.6371.60 3.3572.19a
Cmax (mg ml
1) 0.33670.0913 0.31470.0753 Cmax (mg ml
1) 0.29270.0713 0.72270.193a
Tmax (min) 45 (15–90) 30 (15–60) Tmax (min) 120 (60–240) 45 (15–180)
b
Ae0–24 h (% of DA-8159 dose) 1.4670.735 1.1071.07 Ae0–24 h (% of terazosin dose) 22.275.38 24.7710.3
GI24 h (% of DA-8159 dose) 5.0675.14 3.7273.52 GI24 h (% of terazosin dose) 3.1173.27 2.3772.25
DA-8164
AUC (mg min ml1) 132726.0 123720.7
Termianal t1/2 (min) 2457115 230788.2
CLR (ml min
1 kg1) 0.15170.069 0.13170.167
Cmax (mg ml
1) 0.29470.101 0.30770.100
Tmax (min) 210 (120–360) 180 (120–240)
Ae0–24 h (% of DA-8159 dose) 0.073070.0259 0.075470.0463
GI24 h (% of DA-8159 dose) 0.53970.221 0.45870.258
Abbreviations: Ae0–24 h, percentage of dose excreted in 24 h urine; AUC, total area under the plasma concentration–time curve from time zero to time infinity; CLR,
time-averaged renal clearance; Cmax, peak plasma concentration; GI24 h, percentage of dose recovered from the entire gastrointestinal tract (including its contents
and feces) at 24 h; t1/2, half-life; Tmax, time to reach a Cmax.
Data are expressed as mean7s.d., (without terazosin, n¼ 10; with terazosin, n¼ 9 for DA-8159, without DA-8159, n¼8; with DA-8159, n¼9 for terazosin).
Significant difference from without DA-8159, aPo0.001 and bPo0.05.
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arterial plasma concentration–time profiles of terazosin are
shown in Figure 4a or b, respectively, and some relevant
pharmacokinetic parameters are listed in Table 5. After i.v.
administration of terazosin in rats pretreated with dexa-
methasone phosphate (a major inducer of CYP3A1 and 3A2
in rats), the changes in the pharmacokinetic parameters of
terazosin are as follows: the AUC became significantly
smaller (17.9% decrease), CL and CLNR became significantly
faster (22.4 and 29.8% increase, respectively), CLR became
significantly slower (54.0% decrease) and Ae0–24 h became
significantly smaller (52.5% decrease) than those without
dexamethasone phosphate. After i.v. administration of
terazosin in rats pretreated with troleandomycin (a major
inhibitor of CYP3A1 and 3A2 in rats), the changes in the
pharmacokinetic parameters of terazosin are as follows: the
AUC became significantly greater (74.2% increase), MRT
became significantly longer (106% increase), CL, CLR and
CLNR became significantly slower (42.2, 59.4 and 41.9%
decrease, respectively), and GI24 h became significantly great-
er (582% increase) than those of without troleandomycin.
The aforementioned data suggest that terazosin is metabo-
lized via CYP3A1 and/or 3A2 in rats.
Pharmacodynamic (blood pressure) changes in control rats and
after oral administration of DA-8159, terazosin or both to rats
As DA-8159 and terazosin are available for orally adminis-
tration, the pharmacodynamic effects (lowering blood
pressure) were monitored after p.o. administration of the
drugs. Pharmacodynamic changes after p.o. administration
of DA-8159, terazosin, or both in rats and control rats are
shown in Figure 6. After p.o. administration of DA-8159 or
terazosin alone, the blood pressure changes were not
considerable compared with the controls. However, with
simultaneous administration of terazosin and DA-8159, the
blood pressure was clearly lowered, for up to 7 h, compared
with the blood pressures observed with each drug given
alone. A positive correlation was found (Figure 6) between
the log increase in plasma concentrations of terazosin (the
concentrations with DA-8159 minus the concentrations
without DA-8159) and difference in blood pressure (the
blood pressure with DA-8159 minus the blood pressure with
DA-8159; the values were expressed in terms of þ instead
of  from 15 to 600 min).
Discussion
DA-8164 is a main metabolite of DA-8159 in humans and the
pharmacological effect of DA-8164 in terms of its PDE 5
inhibitory activity is half that of DA-8159 (Kim et al., 2005a).
Hence, the pharmacokinetics of DA-8164 were evaluated in
this study. It was reported (Shim et al., 2003) that the AUC
values of DA-8159 were dose-proportional after i.v. admin-
istration of the drug at doses of 5–30 mg kg1 and p.o.
administration of the drug at doses of 20–30 mg kg1 to male
Sprague–Dawley rats. Hence, the 30 mg kg1 of both i.v. and
p.o. dose of DA-8159 was arbitrarily chosen in this study.
Pharmacokinetic studies on terazosin in rats are scarce. It was
reported (Fort et al., 1984) that LD50s of terazosin were 277
and 293 mg kg1 for male and female rats, respectively, after
i.v. administration of the drug. Hence, the i.v. and p.o. dose
of 5 mg kg1 was arbitrarily chosen in this study.
After i.v. administration of DA-8159 or terazosin alone, the
contribution of the CLR to CL of DA-8159 or terazosin did
not turn out to be considerable: the Ae024 h values of DA-
8159 or terazosin were 6.29 or 28.6% of i.v. dose, respectively
(Table 1). This suggests that most of the i.v. administered
DA-8159 or terazosin are eliminated via the nonrenal route
Table 4 Vmax, Km and CLint for the disappearance of terazosin with or
without DA-8159
Parameter Without DA-8159 With DA-8159
Vmax (nmol min
1 mg protein1) 0.31170.0303 0.26870.0244a
Km (mM) 22.173.42 49.372.41
b
CLint (ml min
1 mg protein1) 0.014270.00134 0.0053970.00102b
Abbreviations: Vmax, maximum velocity; Km, Michaelis–Menten constant;
CLint, intrinsic clearance.
Data are expressed as mean7s.d. (n¼ 5; each). Significant difference from
without DA-8159, aPo0.05 and bPo0.001.
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Figure 4 Arterial plasma concentration–time profiles of terazosin
after i.v. administration of terazosin at a dose of 10 mg kg1 to rats
with (n¼7) or without (n¼8) pretreatment with dexamethasone
phosphate (a) and with (n¼7) or without (n¼8) pretreatment with
troleandomycin (b). Data are presented as mean7s.d.
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(CLNR). The contribution of gastrointestinal (including
biliary) excretion of unchanged DA-8159 or terazosin to
the CLNR of DA-8159 or terazosin seemed almost negligible;
the GI24 h values of DA-8159 or terazosin were 1.46 or
0.245% of the i.v. dose, respectively (Table 1). Moreover, the
percentages of DA-8159 at a p.o. dose of 10 mg kg1 or
terazosin at an i.v. dose of 5 mg kg1 excreted in 24 h bile as
an unchanged drug were o0.1% in rats (n¼5) (Shim et al.,
2003) or 1.96%, respectively, after bile duct cannulation.
Note that the almost negligible values of GI24 h of DA-8159 or
terazosin (Table 1) were not due to degradation of DA-8159
or terazosin in the rat’s gastric fluid; DA-8159 and terazosin
were stable in five rat gastric juices (pHs of 1.5, 1.0, 2.0, 1.5
and 3.0, respectively) using the reported method (Yu et al.,
2003). The above data suggest that the CLNR of DA-8159 or
terazosin listed in Table 1 could represent the metabolic
clearance of DA-8159 or terazosin. Thus, the changes in the
CLNR of DA-8159 or terazosin could represent the metabolic
changes of DA-8159 or terazosin in rats.
After simultaneous single i.v. administration of terazosin
and DA-8159, the slower CLNR of terazosin with DA-8159
could be due to the inhibition of the metabolism of terazosin
by DA-8159 via CYP3A1 and/or 3A2. DA-8159 is metabolized
mainly via CYP3A1 and/or 3A2 in rats (Kim et al., 2005a),
and terazosin is also metabolized via CYP3A1 and/or 3A2 in
rats (Table 5). The hepatic first-pass effect of terazosin was
estimated (Lee and Chiou, 1983) by dividing the CLNR of
terazosin (Table 1) by the reported hepatic blood flow rate of
55.2 ml min1 kg1 (Davies and Morris, 1993) and hemato-
crit of approximately 45% (Mitruka and Rawnsley, 1981) in
rats. The hepatic first-pass effect of terazosin thus estimated
was 59.0%. As, terazosin is an intermediate hepatic extrac-
tion ratio drug, its hepatic clearance depends on the intrinsic
clearance (CLint), free (unbound to plasma proteins) frac-
tions of terazosin in plasma and hepatic blood flow rate in
rats (Wilkinson and Shand, 1975). The significantly slower
CLNR of terazosin by DA-8159 (Table 1) could be supported
by the significantly slower CLint for the disappearance of
terazosin with DA-8159 (Table 4). The contribution of free
fractions of terazosin in plasma and hepatic blood flow rate
to the significantly slower CLNR of terazosin with DA-8159
seemed to be almost negligible; the free fractions of terazosin
were comparable between with and without DA-8159. The
plasma protein binding values of terazosin at a 0.5 mg ml1
were 41.372.79 and 47.578.89% for with and without
DA-8159 at a 0.5mg ml1 in control rats (n¼5), respectively,
using the equilibrium dialysis technique (Shim et al., 2000);
they were not significantly different. DA-8159 had no effect
on hepatic blood flow rate in rats (an internal report). The
plasma protein binding values of DA-8159 at 0.5 mg ml1
were 65.372.35 and 68.477.47% for with and without
terazosin at 0.5mg ml1, respectively; they were also compar-
able between two groups.
After simultaneous p.o. administration of terazosin and
DA-8159, the AUC of terazosin was also significantly greater
than that after terazosin alone (Tables 2 and 3). This could be
for the same reasons as already proposed for the i.v. studies.
However, this was not due to the increase in the gastro-
intestinal absorption of terazosin after simultaneous admin-
istration of DA-8159 because the fractions of terazosin dose
remaining in gastrointestinal tract at 24 h were less than
7.04%. For comparison, the mean ‘true’ fractions of p.o. dose
of terazosin unabsorbed (Funabs) from the gastrointestinal
tract in this study could be estimated using the reported
equations (Lee and Chiou, 1983). The Funabs values thus
estimated were 6.87 and 1.25% for terazosin alone and with
DA-8159, respectively. Thus, more than 93% of p.o. dose of
terazosin was absorbed in both groups of rats. The signifi-
cantly greater AUC of oral terazosin with DA-8159 (Tables 2
and 3) could also be due to inhibition of intestinal
metabolism of terazosin by DA-8159 via CYP3A1 and/or
3A2. This could be supported by rat tissue homogenates
study. After 30 min incubation of 0.1 mg of terazosin with
5 mg of DA-8159 with rat small intestinal homogenates in a
water-bath shaker kept at 371C and 500 o.p.m., the amount
of terazosin remaining in small intestine was significantly
greater (11.8% increase) than that of without DA-8159. Note
that the GI24 h values for both drugs were o7.04% of dose
(Tables 1–3) which could not affect considerably the overall
pharmacokinetics of the two drugs.
The blood pressure lowering effect was considerable after
simultaneous p.o. administration of both drugs than that
after each drug alone (Figure 5), and this could be due to
elevation of plasma terazosin concentration, because of the
Table 5 Pharmacokinetic parameters of terazosin after i.v. administration of terazosin at a dose of 10 mg kg1 to rats without (control) and with
pretreatment with dexamethasone phosphate or troleandomycin
Parameter Control With dexamethasone phosphate With troleandomycin
AUC (mg min ml–1) 430754.6 353778.6a 7497177b
Terminal t1/2 (min) 186731.6 191791.3 219796.3
MRT (min) 97.5717.9 87.0788.1 201781.1c
Vss (ml kg
1) 21807507 160071960 25107792
CL (ml min1 kg1) 23.272.84 28.476.42a 13.473.26b
CLR (ml min
1 kg1) 4.6371.13 2.1371.68a 1.8871.45c
CLNR (ml min
1 kg1) 19.872.85 25.775.20c 11.572.45b
Ae0–24 h (% of terazosin dose) 20.473.11 9.7073.41
b 16.677.53
GI24 h (% of terazosin dose) 0.14870.114 0.20870.289 1.0171.05
a
Abbreviations: Ae0–24 h, percentage of dose excreted in 24 h urine; AUC, total area under the plasma concentration–time curve from time zero to time infinity; CL,
time-averaged total body clearance; CLR, time-averaged renal clearance; CLNR, time-averaged nonrenal clearance; GI24 h, percentage of dose recovered from the
entire gastrointestinal tract (including its contents and feces) at 24 h; MRT, mean residence time; t1/2, half-life; Vss, apparent volume of distribution at steady state.
Data are expressed as mean7s.d. (control, n¼ 8; with dexamethasome phosphate, n¼ 7; with troleandomycin, n¼ 7). Significant difference from control,
aPo0.05, bPo0.001 and cPo0.01.
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inhibition of terazosin metabolism by DA-8159 via CYP3A1
and/or 3A2 (Table 4). A positive correlation was found
between the log increase terazosin plasma concentration and
blood pressure changes (Figure 6). A possible correlation was
also found between log plasma concentrations of prazosin
and blood pressure differences in healthy male volunteers
(Bateman et al., 1979). All these results suggest that p.o. DA-
8159 and terazosin should not be given simultaneously.
Human studies are required to determine the time interval
needed to avoid these interactions between p.o. DA-8159
and terazosin.
Conclusions
After simultaneous i.v. and p.o. administration of terazosin
and DA-8159 to rats, the AUC values of terazosin were
significantly greater than those after terazosin alone (Tables
1, 2 and 3). This could be due to hepatic (both i.v. and p.o.)
and intestinal (p.o.) inhibition of metabolism of terazosin
via CYP3A1 and/or 3A2 by DA-8159 in rats. The blood
pressure lowering effects after simultaneous p.o. administra-
tion of both drugs were considerable compared with those
of each drug alone (Figure 5), and this may be due to
significantly higher plasma concentration of terazosin after
simultaneous p.o. administration of both drugs (Figure 6).
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Figure 6 Relationship between log mean plasma concentration
difference of terazosin (the concentrations with DA-8159 minus the
concentrations without DA-8159) and mean changes in systolic
blood pressure (the blood pressure with DA-8159 minus the
blood pressure without DA-8159; the values were expressed in
terms of þ instead of ) after oral administration of both terazosin
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